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-UXT-V2 is a canonical substrate of SCF(Fbxo7) E3 ubiquitin ligase; 
-Fbxo7 interacts with both UXT-V1 and UXT-V2; 
-UXT-V2 recruits Fbxo7 to the cell nuclei; 
-Fbxo7 inhibit NF-kB pathway through degradation of UXT-V2. 



































































Background: Ubiquitously eXpressed Transcript isoform 2 (UXT-V2) is a prefoldin-like 
protein involved in NF-B signaling, apoptosis, and the androgen and estrogen response. 
UXT-V2 is a cofactor in the NF-κB transcriptional enhanceosome, and its knockdown 
inhibits TNF- -induced NF-B activation. Fbxo7 is an F-box protein that interacts with 
SKP1, Cullin1 and RBX1 proteins to form an SCF(Fbxo7) E3 ubiquitin ligase complex. 
Fbxo7 negatively regulates NF-B signaling through TRAF2 and cIAP1 ubiquitination. 
Methods: We combine Co-immunoprecipitation, ubiquitination in vitro and in vivo, 
cycloheximide chase assay, Ubiquitin chain restriction analysis and microscopy to 
investigate interaction between Fbxo7 and overexpressed UXT-V2-HA. Results: The Ubl 
domain of Fbxo7 contributes to interaction with UXT-V2. This substrate is 
polyubiquitinated by SCF(Fbxo7) with K48 and K63 ubiquitin chain linkages in vitro and 
in vivo. This post-translational modification decreases UXT-V2 stability and promotes its 
proteasomal degradation. We further show that UXT-V1, an alternatively spliced isoform 
of UXT, containing 12 additional amino acids at the N-terminus as compared to UXT-V2, 
also interacts with and is ubiquitinated by Fbxo7. Moreover, FBXO7 knockdown 
promotes UXT-V2 accumulation, and the overexpression of Fbxo7-F-box, protects 
UXT-V2 from proteasomal degradation and enhances the responsiveness of NF-B 
reporter. We find that UXT-V2 colocalizes with Fbxo7 in the cell nucleus. Conclusions: 
Together, our study reveals that SCF(Fbxo7) mediates the proteasomal degradation of 
UXT-V2 causing the inhibition of the NF-B signaling pathway. General significance: 
Discovering new substrates of E3 ubiquitin-ligase SCF(Fbxo7) contributes to understand 






































































 F-box proteins (FBPs) are components of the largest family of SCF-type (SKP1, 
Cullin1 and F-box protein) E3 ubiquitin ligases called SCF1 (SKP1, Cullin1 and F-box 
protein) of the CRLs (Cullin-RING ligases) [1]. FBPs interact through their F-box 
domain with SKP1, which binds to a scaffold protein Cullin 1 and RING-box protein 
RBX1 to form E3 ligase complexes, which are the final players in the enzymatic cascade 
responsible for protein modification with ubiquitin [2–4]. This reversible process is 
catalyzed by three different enzymes: a ubiquitin-activating enzyme (E1), a ubiquitin-
conjugating enzyme (E2), and a ubiquitin ligase (E3). The consequences of this post-
translational modification (PTM) include proteasomal degradation [5] and/or altering the 
localization or activity of the modified protein [6]. Opposing the effect of E3 ubiquitin 
ligases, deubiquitinating enzymes (DUBs) catalyze the removal of ubiquitin from target 
proteins and disassemble polymeric ubiquitin chains, thus changing the fate of substrates 
and maintaining ubiquitin homeostasis in the cell [7]. 
 The dysregulation of FBPs causes a range of different human pathologies, such as 
cancer (reviewed in [8,9]), Parkinson’s disease (PD) [10] and cardiac diseases [11], 
attesting to their importance in the regulation of many cellular processes such as the cell 
cycle, differentiation and development, cell death, and oxidative stress [12]. Fbxo7 is the 
fifth most abundant F-box protein found in SCF complexes in human cells [13]; however, 
many of its described functions, such as cell cycle regulation [14,15] and mitophagy, are 
independent of its SCF(Fbxo7) ubiquitin ligase activity [16]. The effects of Fbxo7 on the 
cell cycle are mediated through its stabilizing interactions with cell cycle proteins, Cdk6 
and p27 [14,17]. Recessive point mutations in FBXO7, also called PARK15, are 
associated with PD [18–21], and deficiencies in mitochondrial homeostasis are emerging 
as a possible cause [16,21,22]. Fbxo7, but not its PD mutants, facilitates mitophagy to 
protect cells from accumulating damaged mitochondria, and upon neurotoxic stress, 
Fbxo7 localizes in mitochondria and forms aggregates. Fbxo7 mutations promote 
deleterious Fbxo7 aggregation in mitochondria, contributing to cell death [22]. 
SCF(Fbxo7) inhibits the NF-κB (nuclear factor-κB) signaling pathway through 
ubiquitination of c-IAP1 (inhibitor of apoptosis) and TRAF2 (23). The neurotrophin 
receptor-interacting MAGE protein (NRAGE), a component of bone morphogenetic 
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ubiquitinated by Fbxo7 up-regulating the NF-κB activity [25]. Other ubiquitinated 
substrates include translocase of outer mitochondrial membrane 20 (TOMM20) and 
glycogen synthase kinase 3β (GSK3β) which were validated as K63-polyubiquitinated 
substrates, suggesting Fbxo7 plays roles in mitochondrial transport and Wnt signaling 
pathway regulation [26]. 
 From the same proteome-wide screen that discovered TOMM20 and GSK3β as 
substrates of SCF(Fbxo7), we also identified Ubiquitously eXpressed Transcript (UXT) 
protein isoform 2, also known as androgen receptor trapped clone-27 (ART-27). UXT is a 
prefoldin-like protein that forms ubiquitously expressed protein-folding complexes in 
human and mouse tissues. Two mRNA splicing isoforms of UXT, termed UXT-V1 and 
UXT-V2, have been described.  They differ in their N-termini, (UXT-V1 (169 aa) is 12 
amino acids longer than UXT-V2 (157 aa) and have distinct functions. While UXT-V2 is 
a transcriptional cofactor that activates NF-κB transcription in the nucleus, UXT-V1 is 
localized in the cytoplasm and modulates TNF-induced apoptosis [27,28]. UXT-V2 also 
regulates the androgen receptor signaling pathway through interactions with Androgen 
Receptor N-terminus [29,30]. In addition, these isoforms have opposing effects in SARM 
(Sterile and HEAT ARMadillo motif-containing protein)-induced apoptosis, with UXT-
V1 promoting a reduction in caspase 8 activity and UXT-V2 increasing caspase 8 activity 
and enhancing apoptosis by activating the extrinsic pathway through depolarization of 
mitochondria [31]. UXT-V2 is also implicated in tumorigenesis, being overexpressed in a 
number of human tumors but not in matching normal tissues. In the cytoplasm, EGFP-
UXT-V2 has been found associated with -tubulin in human centrosomes, and it causes 
mitochondrial aggregation when overexpressed [32,33]. 
 Although Fbxo7 and UXT-V2 are involved in similar cellular processes, such as 
NF-κB signaling and stress-induced mitochondrial aggregation, the interaction between 
these proteins has not been explored. Here, we show that Fbxo7 interacts and 
ubiquitinates both UXT-V1 and UXT-V2, with UXT-V2 being poly-ubiquitinated 
through K48 and K63 polyubiquitin chains. This modification reduces UXT-V2 stability, 
inducing proteasomal degradation. We show that UXT-V2 colocalizes with Fbxo7 in the 
cell nucleus. The knockdown of FBXO7 or the overexpression of the dominant negative 
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overexpression of Fbxo7-F-box, increases TNF- activation of the NF-B signaling 
pathway. 
  
Material and methods 
 
Cell culture 
Human osteosarcoma epithelial cells (U2OS) and human embryonic kidney (HEK) 293T 
cells were obtained from ATCC. The cells were cultured in DMEM high glucose 
(Corning) supplemented with 10% fetal bovine serum (FBS, Gibco) and penicillin (100 
units), streptomycin (100 g) and L-glutamine (0.292 mg/mL) (Thermo Fisher 
Scientific). To passage cells, they were washed once with phosphate buffered saline 1X 
(PBS, HyClone) and detached with trypsin (TrypLe Express, Thermo Fisher Scientific). 
 
Reagents and antibodies  
Cycloheximide (C1988), protease inhibitor cocktail SIGMAFAST™ (S8820), agarose- 
anti-FLAG® M2 (A2220), agarose-anti-HA (E6779) beads, FLAG® peptide (F3290), HA 
peptide (I2149), primers were all purchased from Sigma-Aldrich. Antibodies to HA 
(H3663) (1:1000), FLAG® M2 (F1804) (1:500), Fbxo7 (SAB1407251) (1:1000), GAPDH 
(G8795) (1:10000) and actin (A3853) (1:2000) were purchased from Sigma-Aldrich. 
Rabbit antibodies to Fbxo7 (ARP43128) (1:1000) were purchased from Aviva Systems 
Biology; antibodies against β-actin were purchased from Merck Millipore (MAB1501) 
(1:10000); and against the myc epitope (#2272) (1:1000), anti-K63 polyubiquitin (#5621) 
(1:500), anti-K48 polyubiquitin (#8081) (1:1000), anti-AKT (#4691) (1:1000) anti- 
Histone H3 (1B1B2) (1:1000) were purchased from Cell Signaling Technologies. Human 
ubiquitin (U-100H), ubiquitin N-terminal biotin (UB-560), His-ubiquitin E1 enzyme 
(UBE1) (E-304), UbcH5a/UBE2D1 (E2-616), 10X ubiquitin conjugation reaction buffer 
(B-70), Mg-ATP Solution (B-20) and the proteasome inhibitor MG132 (I-130) were 
purchased from Boston Biochem.  
 
Plasmids and cloning 
Constructs expressing wild-type or mutant Fbxo7 cloned into pcDNA3 or empty vector 
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obtained from Clontech. The pcDNA3-UXT-V2-HA plasmid was constructed from 
pGEX2-UXT (kindly provided by Dr. Chris Bartholomew, Glasgow Caledonian 
University) through PCR using the following primers: sense (EcoRI site) 5' 
CTACGGGAATTCATGGCGACGCCCCCTAAGCGGC 3' and antisense (XhoI site) 
5'ACCGAGCTCGAGCTAAGCGTAATCTGGTACGTCGTATGGGTAATGGTGAGG
CTTCTCTGGGAAATTCTGCAG 3'. This construct was used as a template for the 
construction of UXT-V1-HA by PCR. The extra 12 N-terminal amino acid sequence of 
UXT-V1 was added to the sense primer, while the HA-tag encoding sequence of UXT-
V2-HA was added to the antisense primer. For PCR amplification, 67.5 ng of the sense 
primer (EcoRI site) 
5'ATACTAGAATTCATGGTCTTCCCCCTCCCCACTCCCCAGGAGCCCATCATGG
CGACGCCCCCTAAGC 3' and antisense primer (XhoI site) 5' 
TATGAGCTCGAGCTAAGCGTAATCTGGTACGTCGTATGGGTAATGG 3' was 
used with 10 ng of the template and Phusion Flash High-Fidelity PCR Master Mix 
(Thermo Scientific, USA). The pcDNA3-UXT-V1-M13G-HA plasmid was purchased 
from Epoch Life Science (USA). The siRNA to human FBXO7 was 
5’CUGAGUCAAUUCAAGAUAA3’ obtained from Sigma-Aldrich. 
 
In vitro ubiquitination assays 
For the in vitro ubiquitination assay, the SCF(Fbxo7) complex and Fbxo7 lacking the F-
box domain (Fbxo7-ΔF-box) were purified from HEK293T cells transfected with 
2xFLAG-Fbxo7 or 2xFLAG-Fbxo7-ΔF-box in combination with SKP1-HA, RBX1-myc 
and Cullin1. The cells were lysed with NP-40 lysis buffer (50 mM Tris-HCl pH 7.2, 225 
mM KCl, and 1% NP-40) supplemented with a protease inhibitor cocktail and 
phosphatase inhibitors (10 mM NaF and 1 mM Na3VO4). Cell lysates were centrifuged 
16,900 x g/4oC/20 min and supernatants were subjected to immunoprecipitation (IP) with 
anti-FLAG agarose beads, and the eluates were obtained after elution with FLAG peptide 
(300 µg/mL) during 1h at 4oC. SCF(Fbxo7) or Fbxo7-ΔF-box was used at 25 and 50 nM 
combined with the ubiquitin mix [ubiquitin buffer, E1 (100 nM), E2-UbcH5a (500 nM), 
biotin-ubiquitin (20 mM), Mg-ATP (2 mM)] and UXT-V2-HA purified from HEK293T. 
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In vivo ubiquitination assays 
HEK293T cells were transfected with empty vector, EGFP or FLAG-Fbxo7 constructs 
and UXT-V2-HA or UXT-V1-M13G-HA, with or without ubiquitin-6xHis-myc for 36 h. 
The transfected cells were treated with 10 µM of MG132 6 h prior to lysis. Cells were 
lysed as described in last section and supernatants were subjected to immunoprecipitation 
(IP) with agarose-anti-HA beads. The polyubiquitinated proteins were eluted with HA 
peptide (300 µg/mL), and eluates were resolved with SDS-PAGE and immunoblotted. To 
reprobe immunoblots, membranes were incubated in a Stripping Buffer (SB) (glycine 200 
mM pH 2.0, SDS 0.1%, Tween 1%) at 37oC for 15 min. This incubation was repeated 3 
times, and the membrane was washed with TBST and blocked for 1h with dried milk 5% 
in TBST. Thereafter, the membrane was tested with anti-rabbit-HRP antibody to ensure 
the removal of previous signals. The second probe with rabbit anti-K48 antibody was 
then performed. The images were captured in ChemiDoc XRS+ (BioRad), one image 
each 4s during 200s, before pixel saturation and directly used for analysis. 
 
Ubiquitin chain restriction analysis 
Ubiquitin chain restriction (UbiCRest) analyses were performed as described [26,34]. 
HEK293T cells were transfected for 48 h with UXT-V2-HA and 2xFLAG-Fbxo7 and 
treated 6 h prior to cell lysis with MG132 (10M). The polyubiquitinated UXT-V2-HA 
were immunoprecipitated from HEK293T cells using agarose-anti-HA. The in vivo 
polyubiquitinated substrates were eluted by HA peptide at 300 µg/mL and stored at 
−80°C. Purified deubiquitinating enzymes (DUBs) as described in [36] were diluted with 
2x in dilution buffer (50 mM Tris, pH 7.4, 300 mM NaCl, and 20 mM DTT), added to the 
samples for 30 minutes at 37°C, and reactions were stopped by Laemmli buffer. Samples 
were resolved by SDS–PAGE, and the blots were probed with anti-polyubiquitin (Santa 
Cruz Biotechnology, CA, USA). 
 
Cycloheximide chase assay 
U2OS cells were transfected with 2xFLAG-Fbxo7 or 2xFLAG-Fbxo7-ΔF-box in 
combination with UXT-V2-HA or UXT-V1-M13G-HA. Cells were serum starved for 12 
hours and, where indicated, treated with cycloheximide (40 μg/mL) for 0, 2 or 4 hours in 
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lysis. Cell lysis was performed with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM 
NaCl, 1% NP-40, 1% sodium deoxycholate and 1% sodium dodecyl sulfate) with a 
protease inhibitor cocktail and phosphatase inhibitors as previously described for 30 
minutes on ice. Solutions were centrifuged at 16,900 x g for 45 minutes at 4°C, and 




HEK293T cells were transfected with 100 nM of FBXO7- siRNA 
(CUGAGUCAAUUCAAGAUA) or siRNA universal negative control (Sigma Aldrich) in 
the presence of 0,5 g of UXT-V2-HA by using Lipofectamine 2000, according to the 
manufacturer’s instructions (Thermo Scientific, USA). After 36h, cells were lysates with 
RIPA buffer as described before and the proteins extracts were used to immunoblotting. 
 
Reverse Transcriptase-Quantitative PCR (RT-qPCR) analysis 
Total RNA was extracted from HEK293T cells transfected with pEGFP-N1, pcDNA3 or 
UXT-V2 with the Direct-zol RNA MiniPrep kit (Zymo Research, USA) and treated with 
DNAse I (Invitrogen™, USA) for DNA removal according to the manufacturer’s 
instructions. Samples were quantified with NanoVue™ (GE Healthcare Life Sciences, 
USA), and 300 ng of RNA was reverse transcribed with a High Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher Scientific, USA). cDNA samples were diluted 25x for 
use as a template, and primers were used at 150 nM in a 15 µL reactions with SYBR™ 
Green PCR Master Mix (4309155, Applied Biosystems™, USA). Amplifications were 
carried out in a 7500 Fast Real-Time PCR System (Applied Biosystems™, USA) with the 
following primers: FBXO7 sense: 5' AGTCCCTGCTGTGCACCTG 3', FBXO7 
antisense: 5' CGCTGGAATGTCATCTTGAAGA 3', GAPDH sense: 5' 
AGAAGGCTGGGGCTCATTTG 3', and GAPDH antisense: 5' 
AGGGGCCATCCACAGTCTTC 3'. 
 
Preparation of total and subcellular extracts 
Total levels of Fbxo7 were assessed by transfecting HEK293T cells with pEGFP-N1 or 
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and immunoblotting. For subcellular fraction enrichment, U2OS cells were transfected 
with empty vector or UXT-V2-HA or UXT-V1-M13G-HA in combination with FLAG-
Fbxo7 and lysed with NE-PER® Nuclear and Cytoplasmic Extraction Reagents according 
to the manufacturer's protocol (Thermo Scientific, USA). Supernatants containing the 
protein extracts were submitted to SDS-PAGE and immunoblotting. 
 
NF-B luciferase reporter assay 
HEK293 cells expressing pBIIx-luc (described in [35]) were kindly provided by Dr. 
Dario Zamboni (Department of Cellular and Molecular Biology, Faculty of Medicine of 
Ribeirao Preto, University of Sao Paulo). Cells were cultivated in 96-well Corning 
Costar® plates at 5 x 105 cells/well, and after 24 h, they were transfected with 75 ng of 
each plasmid (pEGFP-N1, 2xFLAG-Fbxo7 or 2xFLAG-Fbxo7-ΔF-box or UXT-V2-HA) 
and 1,5ng of pCMV-Renilla luciferase control plasmid, with Lipofectamine 2000 
(Thermo Scientific). After 24 h, the cells were treated with TNF-α 10ng/mL in serum 
deprived DMEM without phenol red (Gibco) by 12h. Cells were lysed by Dual-Glo 
Luciferase assay kit (Promega), transferred to white plate 96-well Corning Costar® plate 
and Firefly and Renilla luciferase activity measurement were obtained in a SpectraMax i3 
luminometer (Molecular Devices). 
 
Multiphoton microscopy 
U2OS cells were grown on glass coverslips in complete DMEM and transfected with 
UXT-V2-HA, UXT-V1-M13G-HA or 2xFLAG-Fbxo7 with Lipofectamine 2000 
according to the manufacturer (Thermo Scientific, USA). The cells were washed once 
with PBS before being fixed and permeabilized for 10 min at room temperature (RT) with 
PBS containing 2% paraformaldehyde, 0.3% Triton X-100. Subsequently, cells were 
washed three times with PBS and blocked with PBS containing 2% bovine serum 
albumin (BSA) for 1h at RT. Antibody incubations were performed for 1h at RT in PBS 
containing 2% BSA (dilutions: anti-Fbxo7 (Aviva) 1:50; anti-HA (Sigma Aldrich) 1:600)  
followed by incubation with Alexa 488- and Alexa 594-coupled secondary antibodies 
(Thermo Scientific, USA) (dilution 1:800). Coverslips were mounted with Prolong 
diamond antifade mounting medium containing DAPI (Invitrogen). Samples were 
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using objective C-Apochromatic 63X/1.2 W in Laboratório Multiusuário de Microscopia 
Multifoton (LMMM) at the Department of Cellular and Molecular Biology, Faculty of 
Medicine of Ribeirao Preto, University of Sao Paulo, Brazil. 
 
Statistical analysis 
Data were subjected either to unpaired Student’s t-test (when there were only two groups) 
or one-way analysis of variance (ANOVA one-way) or 2way ANOVA with Bonferroni or 
Newman-Keuls pottest. Analyses were performed with Prism (GraphPad Software, 





SCF(Fbxo7) ubiquitinates UXT-V2 in vitro and interacts with UXT-V1 and UXT-V2 
 To validate the identification of UXT-V2 as a substrate of SCF(Fbxo7) from the 
protein microarray study described in (26), we performed an in vitro ubiquitination assay 
with purified SCF(Fbxo7) or mutant Fbxo7-F-box E3 ligases at two different 
concentrations, using purified UXT-V2-HA from HEK293T cells as a substrate. The 
Fbxo7-F-box mutant is unable to form an E3 ligase because it lacks the F-box domain 
that interacts with SKP1, and thus serves as a negative control.  The reactions were 
performed in the presence of a ubiquitin mix composed of E1, E2, ubiquitin, ubiquitin 
buffer and ATP. A concentration dependent smear of polyubiquitinated UXT-V2 was 
observed only in the presence of SCF(Fbxo7), showing the specificity of the in vitro 
ubiquitination assays (Figure 1A). 
 To map the interaction site on Fbxo7 for UXT-V2, HEK293T cells were co-
transfected with plasmids encoding C-terminal HA-tagged UXT-V2 and N-terminal 
2xFLAG-Fbxo7 or various mutants deleting specific domains, either singly or in 
combination. These included the Ubl domain (1–88), a linker region (89–128), the 
proline-rich region (PRR) (399–522) and the F-box domain (335-372). The F-box domain 
deletion did not affect the interaction of Fbxo7 with UXT-V2 (lane 3, Figure 1B), 
indicating that this mutant maintain its substrate binding domain, as also observed 
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linker region substantially reduced its interaction with UXT-V2 (lanes 4 and 6, Figure 
1B). These results, summarized in Figure 1C, suggest that Ubl domain contributes to the 
interaction of Fbxo7 with UXT-V2. 
 In addition to isoform 2, another splice variant, UXT-V1, which is 12 amino acid 
residues longer than UXT-V2 at the N-terminus, has been described [27,36] (Figure 1D). 
We observed that UXT-V1 plasmid also produced UXT-V2 isoform through translation 
at a second methionine at codon 13, ATG2. To bypass this issue, we obtained an UXT-
V1 version with glycine substitution at ATG2 to produce UXT-V1-M13G, which 
prevented expression of UXT-V2 (Figure 1D). To analyze the cellular distribution of both 
UXT isoforms, we carried out Multiphoton microscopy in U2OS cell lines transfected 
with UXT-V2-HA or UXT-V1-M13G-HA. We observed that both isoforms are present in 
the cytosol and cell nuclei, with UXT-V1-M13G being predominantly cytoplasmic and 
UXT-V2 within nuclei (Figure 1E). We notice a punctate pattern in the cytoplasm upon 
transient expression of UXT-V1-M13G-HA and UXT-V2-HA. Punctate expression has 
been previously noted upon overexpression of UXT-V2 [37,38].  
 These isoforms have different functions and cellular localization, so we evaluated 
the in vivo interaction of both with Fbxo7, using co-immunoprecipitation assays. We 
observed that, similar to UXT-V2, UXT-V1-M13G also interacted with Fbxo7 (Figure 








































































Figure 1- Fbxo7 ubiquitinates UXT-V2 in vitro and interacts with UXT-V2 and UXT-V1 
in vivo. A) In vitro ubiquitination assays using purified SCF(2xFLAG-Fbxo7) or 
2xFLAG-Fbxo7 lacking the F-box domain in two different concentrations (25 and 50 
nM) and purified UXT-V2 from HEK293T cells as a substrate. The samples were used 
for western blotting, and an anti-HA antibody was used to visualize polyubiquitinated 
UXT-V2. The smear of each band was quantified by densitometry using Image J and the 
+/- SEM of the triplicates was calculated by GraphPad Prism; LC (light chain). B) 


































































UXT-V2 is a canonical substrate of the E3 ligase SCF(Fbxo7) 
 
 13 
UXT-V2-HA were immunoprecipitated with agarose anti-FLAG. Input and eluted 
proteins were subjected to immunoblotting with the indicated antibodies. C) Summary of 
the interaction mapping between UXT-V2 and Fbxo7 proteins. D) Representation of 
UXT-V1, UXT-V1-M13G and UXT-V2 isoforms and their expression in HEK293T cells 
transfected with each plasmid. E) Multiphoton microscopy of U2OS transfected with 
UXT-V1-M13G-HA or UXT-V2-HA. The slides were incubated with anti-HA and nuclei 
were probed by DAPI. F) HEK293T cells were transfected with FLAG-Fbxo7 and UXT-
V1-M13G or UXT-V2. The cellular extracts were immunoprecipitated, resolved by SDS-
PAGE and probed with the indicated antibodies. All the inputs represent 3% of the total 
protein used in coimmunoprecipitation assays. All cell lysates were obtained by NP-40 
lysis buffer.  
 
Fbxo7 mediates proteasomal degradation of UXT-V2 but not UXT-V1-M13G 
 
 To investigate the functional consequences of polyubiquitination of UXT-V2 and 
UXT-V1-M13G by Fbxo7, we carried out a cycloheximide (CHX) chase analysis to 
evaluate the substrate stabilities in vivo. Different from previous cell lysis performed in 
Figures 1B, 1F and 2A where we used NP-40 lysis buffer because of co-
immunoprecipitation experiments, in CHX assays we lysed cells with RIPA buffer. The 
NP-40 lysis buffer did not lyse the cell nuclei completely compared to RIPA buffer, as 
can be seen in the immunoblots for the nuclear marker histone H3, which is clearly higher 
when RIPA was used (Figure 2A). Similar to Figure 2C, it is also evident that using NP-
40 buffer results in higher UXT-V2 levels when co-expressed with Fbxo7 compared to 
Fbxo7-F-box. However, the opposite result was obtained when RIPA was utilized, i.e. 
UXT-V2 expression is higher in the presence of Fbxo7-F-box (Figure 2A). 
 Since both UXT-V1-M13G and UXT-V2 interact with Fbxo7 and UXT-V2 were 
confirmed as substrate through in vitro ubiquitination assay, we performed in vivo 
ubiquitination assays in HEK293T cells to evaluate whether they are both substrates of 
SCF(Fbxo7). Cells were transfected with plasmids encoding C-terminal HA-tagged UXT-
V1-M13G or UXT-V2 in combination with ubiquitin-myc and Fbxo7 or the negative 
controls peGFP-N1 and the ligase dead mutant, Fbxo7-F-box. Therefore, although the 
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substrates. The proteasome inhibitor MG132 was used to allow accumulation of poly-
ubiquitinated proteins in the cells, and immunoprecipitation with agarose anti-HA was 
carried out. A strong smear signal of poly-ubiquitinated protein was seen when Fbxo7 
was co-expressed with UXT-V2 and UXT-V1-M13G confirming that both isoforms of 
UXT are SCF(Fbxo7) substrates (Figure 2B).  
 U2OS cells were transfected with plasmids encoding UXT-V2-HA or UXT-V1-
M13G-HA and Fbxo7 or Fbxo7-F-box. The cells were either left untreated or incubated 
for 2 or 4 h with CHX, and the levels of UXT-V2-HA in the lysates were evaluated. 
UXT-V2 levels were reduced to 50% of their initial amount after 2 h of treatment when 
co-expressed with Fbxo7, and only 20% of the protein remained after 4 h (Figure 2C). By 
contrast, even after 4 h of treatment, 80% of UXT-V2 was present in cell lysates when 
Fbxo7-F-box was co-expressed (Figure 2C). These results indicate that Fbxo7 decreases 
the stability of UXT-V2 in an F-box domain-dependent manner. On the other hand, the 
reduction of UXT-V1-M13G levels after 2 and 4 h of treatment was comparable between 
WT and mutant Fbxo7, indicating that its degradation was not mediated by Fbxo7 (Figure 
2D). To prove that UXT-V2 polyubiquitination directs its degradation by the proteasome 
we performed a CHX assay on Fbxo7-transfected cells in the presence of the proteasome 
inhibitor MG132. Strikingly, MG132 treatment inhibited UXT-V2 degradation by the 
proteasome when co-expressed with Fbxo7 WT (Figure 2E), confirming that this 
ubiquitin-ligase promotes the proteasomal degradation of UXT-V2 in cells. 
 The linkage type of the polyubiquitin chains added to substrates by E3 ubiquitin 
ligases determines their fate in the cell [39]. K48 poly-ubiquitin chains often regulate 
protein stability by directing the substrate to the proteasome, while the K63 chain is a 
nondegradative modification related to protein regulation [7]. To determine the type of 
ubiquitin chains added by SCF(Fbxo7) to UXT-V2, we applied ubiquitin chain restriction 
analysis using deubiquitinating enzymes (DUBs) called (UbiCRest) [34]. We used UXT-
V2 obtained by immunoprecipitating UXT-V2-HA from cells transfected with Fbxo7, as 
shown in Figure 2B (lane 6). Polyubiquitinated UXT-V2 was treated with a panel of 
specific DUBs, including two positive controls, USP21 and vOTU, which are nonspecific 
DUBs that are capable of cleaving all types of ubiquitin chains containing isopeptide 
bonds (lanes 2 and 3, Figure 2F). Treatment with the K48-specific DUB OTUB1 reduced 


































































UXT-V2 is a canonical substrate of the E3 ligase SCF(Fbxo7) 
 
 15 
1, Figure 2F). Additionally, a diminished intensity of the poly-ubiquitinated UXT-V2 
smear was observed when increasing concentrations of the K63- selective OTUD1 were 
applied (lanes 7 and 8, Figure 2F), while enzymes targeting K11 (Cezanne) and M1 
(OTULIN) linkages had no effect. To confirm the polyubiquitin chain types present on 
UXT-V2-HA in vivo, we probed the in vivo ubiquitinated samples with anti-K48 or anti-
K63 specific antibodies. Strikingly, we observed both polyubiquitin chains in UXT-V2-
HA confirming the results of UbiCRest assay (Figure 2G). Taken together, these data 
shows that Fbxo7 promotes proteasomal degradation of UXT-V2 through introduction of 
K48 polyubiquitin chains. It remains to be determined the nature of polyubiquitin chain 
introduced in UXT-V1-M13G-HA and the function of K63-linked ubiquitin chains in 
UXT-V2. 
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Figure 2- SCF(Fbxo7) ubiquitinates in vivo both isoforms of UXT and promotes 
proteasomal degradation of UXT-V2. A) UXT-V2 levels in cellular extracts obtained by 
cell lysis with NP-40 or RIPA buffer. HEK293T cells were transfected with indicated 
plasmids and the pellets were lysed with NP-40 or RIPA buffer. Total protein lysates (40 
g) were loaded in gel and the levels of UXT-V2 co-expressed with Fbxo7 or Fbxo7-F-
box were analyzed. This blot is representative of a triplicate experiment. B) HEK293T 
cells were transfected with the indicated plasmids, and the total cell lysates were 
immunoprecipitated with anti-HA. The HA peptide-eluted fractions were resolved by 
SDS-PAGE and used for western blot analyses with the indicated antibodies. The ratio 
between densitometry of the each smear and the corresponding anti-HA band is indicated. 
C) U2OS cells were transfected with Fbxo7 or Fbxo7-F-box in combination with UXT-
V2 or UXT-V1- M13G (D) and treated (2 or 4 h) with cycloheximide (CHX) for 
indicated times. Protein extracts were separated by SDS-PAGE, and the immunoblots 
were probed with the indicated antibodies. The quantitative analysis of the bands was 
performed by Image J and is shown in the graph. E) Similarly, CHX chase assay was 
performed in the presence or absence of the proteasome inhibitor MG132. The graph 
below shows the densitometric analysis by ImageJ of each protein band revealed by the 
indicated antibodies.  GraphPad Prism was used to statistical analysis 2way ANOVA 
(Bonferroni posttest) Assays were performed in biological triplicate. *: p ≤ 0.05 and ** p 
≤ 0.01. F) Purified DUBs were used to map polyubiquitinated UXT-V2 purified from 
HEK293T cells. The nonspecific DUBs (USP21 and vOTU) cleaved all ubiquitin chains; 
OTUB1 (K48-specific) partially removed ubiquitin chains and OTUD1 (preference for 
K63 linkages) showed concentration-dependent activity against the substrate. G) A 
fraction of the eluted proteins from A was subjected to western blot analysis with anti-
K48 or anti-K63 specific antibodies. The ratios indicate the densitometry of each smear 
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FBXO7 knockdown and Fbxo7-F-box expression promote UXT-V2 accumulation  
 To explore the effect of Fbxo7 expression on UXT-V2-HA protein levels in 
different cell lines, HEK293T or U2OS were co-transfected with Fbxo7 or Fbxo7-F-box 
and UXT-V2-HA, and the total cell lysates were analyzed by western blot. When UXT-
V2 was co-expressed with Fbxo7-F-box, we observed an accumulation of this substrate 
when compared to WT Fbxo7 in both cell lines (Figure 3A). These results suggest that 
Fbxo7-F-box interact with UXT-V2-HA and prevented its ubiquitin-mediated 
degradation by Fbxo7. To show the dominant negative effect of Fbxo7-F-box in UXT-
V2-HA, we co-transfect cells with empty vector or Fbxo7-F-box in the presence of 
UXT-V2-HA. Strikingly, Fbxo7-F-box promoted an accumulation of UXT-V2-HA 
compared to empty vector (Figure 3B). To confirm that UXT-V2-HA levels were 
specifically controlled by Fbxo7, we knocked down FBXO7 and evaluate UXT-V2-HA 
levels in total cell lysates. We observed an accumulation of UXT-V2-HA compared to the 
siRNA control (Figure 3C), suggesting that Fbxo7 regulates UXT-V2-HA protein levels 









































































Figure 3- UXT-V2 is a substrate of Fbxo7. A) HEK293T or U2OS cell lines were 
transfected with indicated plasmids, and cell lysates were immunoblotted with indicated 
antibodies. The graphs show the densitometric analysis of the UXT/actin ratio. B) 
HEK293T cells were co-transfected with empty vector or Fbxo7-F-box in the presence 
of UXT-V2-HA and total cell lysates were used to western blotting probed with indicated 
antibodies. C) U2OS cells were transfected with siRNA control or siRNA to FBXO7. 
After 48h, the cell lysates were resolved in SDS-PAGE and immunoblotted with the 
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was used to plot the graphs and statistical analysis (Student’s t-test). All the assays were 
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UXT-V2 colocalizes with Fbxo7 into the cell nucleus 
 Fbxo7 has been reported to be localized in the nucleus when fused with dsRED at 
its C-terminus [14] or to both the nucleus and cytoplasm when N-terminally tagged with a 
FLAG-epitope [40]. The localization of FLAG-Fbxo7 depends on the cell cycle phase, 
being cytoplasmic during G0/G1 and accumulating in the nucleus as cells transition into 
S/G2 phase [40]. In human dopaminergic SK-N-SH cells, overexpressed Fbxo7 forms 
protein aggregates in the cytoplasm, and this effect is time- and stress-dependent [22]. To 
investigate the interaction between Fbxo7 and UXT-V2 at a subcellular level, we 
evaluated the effect of UXT-V2 expression on the localization of Fbxo7. We performed a 
cellular fractionation with cells overexpressing UXT-V2 or a control plasmid and assayed 
Fbxo7 levels in each cell compartment by immunoblotting. We found UXT-V2 
expression increased the levels of Fbxo7 in the nuclear fraction (Figure 4A). To confirm 
that this effect is specific for UXT-V2, we evaluated the localization of Fbxo7 upon 
overexpression of UXT-V1-M13G. Notably, the expression of this longer UXT isoform 
did not alter the subcellular distribution of Fbxo7 (Figure 4B). To further test the 
opposing effects of both UXT isoforms on Fbxo7 localization, we performed a 
Multiphoton microscopy of U2OS cells co-transfected with Fbxo7 and either UXT-V1-
M13G or UXT-V2. Consistent with previous studies (38), Fbxo7 is distributed in the 
cytosol and nucleus (Figure 4Ci). When Fbxo7 was co-expressed with UXT-V1-M13G, 
we observed that Fbxo7 adopted a dotted distribution in cell nuclei (Figure 4Cii). On the 
other hands, Fbxo7 colocalizes with co-expressed UXT-V2 into the cell nucleus, 
exhibiting a predominantly nuclear localization (Figure 4Ciii), compared to Figure 4Ci. 
These results suggest two alternative hypotheses: UXT-V2 increases the total levels of 
Fbxo7 or promotes its nuclear accumulation. However, overexpressing UXT-V2 did not 
affect Fbxo7 protein or mRNA levels in HEK293T cells (Figures 4D and E), indicating 







































































   
Figure 4- UXT-V2 overexpression promotes Fbxo7 translocation to the cell nucleus. A 
and B) U2OS cells were transfected with the indicated plasmids, and the cytosolic- and 
nuclear-enriched fractions were resolved by SDS-PAGE and analyzed by western blotting 
with the indicated antibodies. Histone and Akt were probed as nuclear and cytoplasmic 
markers, respectively. GraphPad Prism was used to statistical test (Student’s t-test), and 
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were transfected with (i) Fbxo7, (ii) Fbxo7 and UXT-V1-M13G or (iii) Fbxo7 and UXT-
V2. The slides were incubated with anti-HA or anti-Fbxo7 and visualized by goat anti-
rabbit-Alexa 488 or donkey anti-mouse-Alexa 594. Nuclei were stained with DAPI and 
an objective of 63x was used. D) HEK293T cells were transfected with pEGFP-N1 or 
UXT-V2-HA, and total cell lysates were resolved by SDS-PAGE and immunoblotted 
with the indicated antibodies. The Fbxo7 protein levels are presented in the graph with 
densitometry values obtained by ImageJ. E) mRNA was purified from HEK293T cells 
transfected with pcDNA3, UXT-V2-HA or peGFP-N1. RT-qPCR analysis was carried 
out for FBXO7 expression and evaluated in comparison to the GAPDH. No significant 
differences were found among the groups (n=3) by using one-way ANOVA (p value = 
0.4807). 
 
Fbxo7 inhibits the NF-B signaling pathway 
 UXT-V2 is an essential component of the NF-B enhanceosome in the nucleus, 
interacting with p65 and modulating the TNF- response [28]. UXT-V2 also interacts 
with EZH1 and SUZ12 in the nucleus to synergistically regulate this pathway [41]. UXT-
V2 knockdown, but not its overexpression, impairs the transcriptional activation of NF-
κB target genes induced by TNF-α [28,41]. To evaluate the consequences of UXT-V2 
degradation by Fbxo7 on the NF-κB pathway, we transfected HEK293 cells stably 
expressing a reporter gene for the NF-κB pathway fused to firefly luciferase. UXT-V2 
was transfected in combination with peGFP-N1, Fbxo7 or  Fbxo7-ΔF-box mutant, and the 
cells were stimulated by TNF-α. Strikingly, Fbxo7 decreased NF-κB pBIIx reporter gene 
levels compared to UXT-V2 with peGFP or UXT-V2 in combination with Fbxo7-ΔF-box 
(Figure 5). These results are consistent with the proteasomal degradation of UXT-V2 







































































Figure 5- Fbxo7 impairs the NF-B signaling pathway. HEK293 cells stably expressing 
the NF-B-luciferase reporter gene were transfected with the indicated plasmids along 
with a Renilla luciferase reporter as a transfection control. After 24 h of transfection, the 
cells were stimulated with TNF-α during serum starvation and harvested. After 48 h, cells 
were harvested and luciferase expression was assayed in quintuplicate from cell lysates 
and luciferase levels were normalized to Renilla levels. *: p < 0.05, **: p= 0.01, ***; p< 




 Different approaches for E3 ubiquitin ligase substrate identification have been 
developed, including in vivo protein partner searching, such as by co-
immunoprecipitation and mass spectrometry, two-hybrid screening and protein 
microarrays [42]. Previously, we reported the identification of 338 new Fbxo7 substrates 
by using in vitro ubiquitination of protein microarrays, and one of these targets was the 
UXT-V2 protein. Since Fbxo7 and UXT-V2 are involved in similar processes, such as 
cellular transformation and NF-B signaling regulation [14,23,28,29], we investigated the 
relationship between these proteins. 
 The Protoarrays are composed of proteins immobilized via the N- or C-terminus 
to a nitrocellulose-activated surface, which can alter the UXT-V2 structure, forcing the 
interaction with Fbxo7. To bypass this constraint, we mapped the in vivo interaction 
between these proteins through co-immunoprecipitation assays. In addition to the F-box 
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(ubiquitin-like; 1-74), Cdk-binding (129-169), FP (Fbxo7/PI31; 173-224) and a PRR 
(proline-rich region; 423-522). The Ubl domain is responsible for the Fbxo7 interaction 
with TOMM20 and GSK3 [26], and we observed that the Ubl domain also contributes to 
Fbxo7 interaction with UXT-V2. To validate the direct ubiquitination of UXT-V2 by 
SCF(Fbxo7), we carried out an in vitro ubiquitination assay with UXT-V2 and 
SCF(Fbxo7) complexes purified from HEK293T cells. We observed that UXT-V2 was 
only poly-ubiquitinated by wild-type Fbxo7, confirming it as a bona fide substrate of this 
E3 ligase. It has been reported that Epstein-Barr virus (EBV) BGLF4 kinase 
phosphorylates UXT-V2 at Thr3, a modification which reduces its interaction with NF-
κB transcription factors and decreases NF-κB enhanceosome activity [43]. It is possible 
that the phosphorylation of UXT-V2 may also promote Fbxo7-mediated ubiquitination 
and degradation, although we did not test for this.  To date no mammalian kinases have 
been reported to phosphorylate UXT-V2, but we cannot exclude that post-translation 
modification of UXT-V2 mediates its interaction with and ubiquitination by SCF(Fbxo7). 
 Another splice variant of UXT called UXT-V1 that is 12 amino acids longer than 
UXT-V2 at the N-terminus, where it binds to TRAF2). It has been described as a short-
lived cytoplasmic protein that protects cells against TNF-induced apoptosis through its 
interaction with TRAF2, which prevents the TRAF2-RIP-TRADD complex from 
recruiting FADD and caspase 8 [36]. Because of the high structural identity with UXT-
V2, we evaluated the interaction of UXT-V1 with Fbxo7. The plasmid encoding UXT-V1 
also expressed UXT-V2 due to an alternative internal ATG codon at position 37. Thus, 
we obtained an UXT-V1-M13G with a mutation at the second ATG, which only produce 
the isoform 1. This clone obviates UXT-V2 expression from the plasmid. We evaluated 
the localization of UXT-V2-HA and UXT-V1-M13G-HA in U2OS cells transfected with 
these plasmids using Multiphoton microscopy. Our results differ from the described by 
Huang, Y. et. al (29); however some differences in the choice and placement of fusions to 
enable detection between our studies could account for this, including our study of the 
only UXT-V1-M13G variant; we used an HA tag at the C-terminus and the Huang, et al. 
used an N-terminal GFP fusion.  This results in proteins with different molecular weights, 
with UXT-V1-M13G-HA (~20kDa) and GFP-UXT-V1 (~45kDa). We also confirmed 
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UXT-V1 and UXT-V2 interact with Fbxo7, indicating that the TRAF2 binding site of 
UXT-V1 [36] is not essential for this interaction. 
 To verify that the ubiquitination of UXT-V2 by SCF(Fbxo7) reported in [26] also 
occurs in the cells, we performed an in vivo ubiquitination assay. Moreover, we compared 
the ubiquitination of UXT-V1-M13G and UXT-V2, to independently assess the ability of 
each isoform to be ubiquitinated, since there are no lysine residues inside the additional 
12 amino acid sequence of UXT-V1. Importantly, both isoforms of UXT were 
ubiquitinated by SCF(Fbxo7), indicating that the TRAF2 binding domain of UXT-V1 is 
not required for interaction or ubiquitination of UXT-V1 by Fbxo7.  
 Polyubiquitination is a reversible post-translational modification that regulates 
many biological processes such as cell-cycle progression, DNA repair, apoptosis, receptor 
endocytosis [39]. Ubiquitin can be attached to a substrate either as a monomer or as a 
polyubiquitin chain with different lengths and linkage types. The distinct conformational 
structure that ubiquitin chains adopt determines their different functions [7]. To evaluate 
the functional relevance of UXT-V1 and UXT-V2 ubiquitination by Fbxo7, we evaluated 
the stability of these proteins in the presence of Fbxo7 or Fbxo7-F-box through CHX 
assays. We showed that Fbxo7 modulates the abundance of UXT-V2 in cells, decreasing 
its half-life when Fbxo7 wild-type was co-expressed. In contrast, we observed that  
degradation of UXT-V1-M13G was independent of E3 ligase function of Fbxo7, once no 
differences were evident when Fbxo7-F-box was used. It worth to mention that RIPA 
buffer was utilized in these assays once we observed that NP-40 buffer used in co-IP 
assays did not disrupt cell nuclei. Interestingly, the levels of UXT-V2 decreased when co-
expressed with Fbxo7 compared to Fbxo7-F-box in cell lysates with RIPA buffer, and 
the contrary was observed when NP-40 buffer was used. Thus, as the translation occurs in 
the cytoplasm and UXT-V2 is being degraded by Fbxo7 WT, the mechanism to replace 
the UXT-V2 is increasing its levels, which is observed predominantly in the cytosol. 
However, when RIPA buffer is used to efficiently lyse nuclei, we observe lower levels of 
UXT-V2 in the presence of Fbxo7. 
 To characterize the ubiquitin chain added to this substrate we carried out 
UbiCRest assay and used specific antibodies against K48 and K63 linkages. The 
UbiCRest assay showed that UXT-V2 was modified by both K48 and K63 polyubiquitin 
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antibodies, we confirmed both Ub-chain types on UXT-V2. The K48 modification is 
associated with the proteasomal degradation of substrates, and we confirmed that Fbxo7 
modulates the abundance of UXT-V2 in cells, decreasing its half-life when Fbxo7 wild-
type was co-expressed by CHX assays. The knockdown of FBXO7 increased UXT-V2 
levels in the cells, and the co-expression of Fbxo7-F-box with UXT-V2 in two different 
cell lines, promoted its accumulation as compared to its co-expression with wild-type 
Fbxo7. This suggests that mutant Fbxo7 protects UXT-V2 from degradation and we 
confirmed its dominant negative effect when co-expressed with UXT-V2-HA compared 
to empty vector. Overall, these results show UXT-V2 is a canonical substrate of Fbxo7.  
 It was reported that a tumor suppressor protein lysyl oxidase proenzyme 
propeptide region (LOX-PP) interacts with UXT-V2 and relocalizes this substrate to the 
cytoplasm, decreasing its stability [44]. Since most of the catalytically active proteasomes 
are localized in the cytoplasm [45], we speculate that polyubiquitinated UXT-V2 is 
translocated to the cytosol for degradation by the proteasome. Whether LOX-PP is the 
protein responsible for mediating this process remains to be evaluated in future studies. 
 We also observed the some K63 ubiquitin chains on UXT-V2, which is a 
proteasome-independent modification related to signal transduction regulation. Recently, 
it was described that K63 chains are seeds for K48/K63 branched ubiquitin chains that 
mediate substrate degradation. The K63 chain in the proapoptotic regulator TXNIP 
introduced by the E3 ligase ITCH triggers the assembly of K48/K63 branched chains by 
recruiting the ubiquitin-interacting ligase UBR5, leading to proteasomal degradation of 
TXNIP [46]. Fbxo7 has a ubiquitin-like domain at the N-terminus, which is important for 
its interaction with UXT-V2 and other described substrates (TOMM20 and GSK3), but 
it remains unknown whether Fbxo7 mediates K63/K48 branched polyubiquitin or 
whether it functions as a K63-interacting E3 ligase to promote the addition of the K48 
ubiquitin chains to this substrate. 
 Fbxo7 has a functional leucine-rich nuclear export sequence (NES) embedded 
within the F-box domain that binds to exportin 1 (CRM1), allowing Fbxo7 to migrate to 
the nucleus. The interaction with CRM1 competes with SKP1 inhibiting SCF(Fbxo7) 
formation, and this competitive mechanism allows Fbxo7 to be present in different 
cellular compartments [40]. Since UXT-V2 is a predominantly nuclear protein, we 
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demonstrated that UXT-V2 overexpression increased the Fbxo7 content in the nucleus, 
suggesting that the functional relevance of the interaction between these proteins is 
associated with a nuclear process. In fact, the Multiphoton microscopy showed that the 
subcellular distribution of Fbxo7 changed when co-expressed with UXT-V2, colocalizing 
with its substrate in the nucleus. The specificity of this effect was demonstrated by UXT-
V1, where no changes in Fbxo7 distribution were observed when these proteins were co-
expressed. We cannot exclude the possibility that UXT-V2 overexpression stabilizes 
Fbxo7 in the cell nucleus either by preventing Fbxo7 association with the nuclear export 
machinery or by preventing its autoubiquitination. 
 Fbxo7 has opposing functions in the NF-kB signaling pathway depending on the 
receptor involved. While Fbxo7 positively regulates formation of the BMPR–NRAGE–
TAK1–TAB1 complex up-regulating NF-κB activity [25], it also negatively regulates this 
pathway by ubiquitinating TRAF2 and cIAP-1, which decreases RIP1 ubiquitination and 
diminishes NF-B signaling [23]. Since UXT-V2 is a component of the NF-B 
enhanceosome in cell nuclei, and its knockdown decreases TNFR activation of this 
pathway [28], we explored the role of Fbxo7 through this receptor. We showed that 
Fbxo7 decreased the activation of NF-B signaling in the presence of UXT-V2, whereas 
overexpression of this substrate with pEGFP restored the activation of this pathway. 
When compared the co-transfection of UXT-V2 with WT Fbxo7 or with Fbxo7-F-box, 
we observed an increase in NF-B signaling by the Fbxo7-F-box mutant, suggesting 
that it interacts with and protects UXT-V2 from degradation caused by Fbxo7, promoting 
the activation of the NF-B signaling pathway. However, Fbxo7-F-box also inhibits the 
activation of this signaling compared to the control. It has been demonstrated that Fbxo7-
F-box predominantly localizes in the nucleus, and we observed a stable interaction 
between Fbxo7-F-box and UXT-V2 in co-IP assays. We hypothesize that the interaction 
between these proteins could sequester UXT-V2 impairing its capacity to assemble the 
enhanceosome and consequently reducing the activation of NF-B genes. It has been 
shown that polyubiquitin chains branched at K48 and K63 regulate NF-B signaling. The 
E3 ligase HUWE1 generates K48 branches on K63 chains formed by TRAF6, and these 
K48-K63 branched chains recruit TAB2, which protects the K63 linkages from CYLD-
mediated deubiquitination, thereby amplifying NF-κB signals [46]. It remains to be 
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